- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00723216
Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
April 2, 2010 updated by: Sanofi
Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days for Prevention of Venous Thromboembolism in Patients With Curative Abdominal Cancer Surgery. Physical Prophylaxis Only Arm [Intermittent Pneumatic Compression (IPC)] Will be Used as an Indicator of Event Rates.
The primary objective of this study is to evaluate the effects of enoxaparin on venous thromboembolism incidence and bleeding rate (major and minor bleeding) in patients undergoing curative abdominal cancer surgery.
The secondary objective is evaluate the incidence of adverse events of enoxaparin in these patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
151
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Malignant tumor patients undergoing laparotomy for which surgery is expected to take 45 minutes or more.
Exclusion Criteria:
- surgery under laparoscope and other endoscopic operations
- clinical signs of deep vein thrombosis
- use of non-steroidal anti-inflammatory drugs from surgery completion until initial administration
- severe hepatic disease or renal disease
- women of childbearing potential, pregnant or lactating.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Enoxaparin
|
20 mg twice a day
|
Other: 2
Intermittent Pneumatic Compression (IPC)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Venous thromboembolism incidence
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of deep vein thrombosis, pulmonary thromboembolism, and venous thromboembolism incidence except patients with thrombus only in muscle veins, and incidence of proximal vein thrombosis
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: International Clinical Development, Clinical Study Director, Sanofi
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (Actual)
December 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
July 24, 2008
First Submitted That Met QC Criteria
July 25, 2008
First Posted (Estimate)
July 28, 2008
Study Record Updates
Last Update Posted (Estimate)
April 5, 2010
Last Update Submitted That Met QC Criteria
April 2, 2010
Last Verified
April 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EFC10094
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abdominal Neoplasms
-
Peking University Third HospitalRecruiting
-
Tianjin Medical University Cancer Institute and...UnknownAbdominal Infection | Abdominal TumorChina
-
M.D. Anderson Cancer CenterRecruitingIntra-abdominal CancerUnited States
-
National Taiwan University HospitalUnknownSymptomatic Abdominal TumourTaiwan
-
Assiut UniversitySouth Egypt Cancer InstituteCompletedPostoperative Analgesia | Lower Abdominal CancerEgypt
-
Duke UniversityMakerere University; Uganda Cancer InstituteNot yet recruiting
-
Catholic University of the Sacred HeartCompletedAbdominal NeoplasmsUnited States, France, Italy, Japan
-
Assiut UniversityUnknown
-
Assiut UniversityNot yet recruiting
-
The Netherlands Cancer InstituteCompletedAbdominal CancerNetherlands
Clinical Trials on enoxaparin
-
Indonesia UniversityPT Metiska FarmaCompleted
-
Oregon Health and Science UniversityNational Trauma Research Institute; Medical Research Foundation, OregonCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
University of OuluUniversity of HelsinkiUnknownIntracerebral HemorrhageFinland
-
Peking Union Medical College HospitalCompletedCoronary Artery Disease | Percutaneous Coronary InterventionChina
-
Lebanese American UniversityCompletedRenal Impairment | Venous ThromboembolismLebanon
-
PT Bio FarmaRecruiting
-
Portola PharmaceuticalsCompleted
-
University of UtahUniversity of MichiganCompletedSurgery | Venous Thromboembolism | Deep Venous ThrombosisUnited States
-
Wake Forest University Health SciencesTerminated